Sirolimus in Liver Transplant Recipients with Hepatocellular Carcinoma: An Updated Meta-Analysis

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin. 2011;61(2):69–90. PMID:21296855.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76. doi:10.1053/j.gastro.2007.04.061. PMID:17570226.
   PubMed Web of Science ®Google Scholar
• De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol. 2014;15(1):23–34. doi:10.1016/S1470-2045(13)70546-1. PMID:24314615.
   PubMed Web of Science ®Google Scholar
• Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: Prevention strategy and planning. World Journal Of Hepatol. 2015;7(12):1708–17. doi:10.4254/wjh.v7.i12.1708.
   PubMed Web of Science ®Google Scholar
• Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma–an updated analysis of randomized controlled trials. Alimentary Pharmacol Therapeutics. 2006;23(11):1535–47. doi:10.1111/j.1365-2036.2006.02932.x.
   PubMed Web of Science ®Google Scholar
• Moini M, Schilsky ML, Tichy EM. Review on immunosuppression in liver transplantation. World J Hepatol. 2015;7(10):1355–68. doi:10.4254/wjh.v7.i10.1355. PMID:26052381.
   PubMed Web of Science ®Google Scholar
• Elsharkawi M, Staib L, Henne-Bruns D, Mayer J. Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation. 2005;79(7):855–7. doi:10.1097/01.TP.0000154913.88193.FF. PMID:15818333.
   PubMed Web of Science ®Google Scholar
• Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg. 2008;248(5):857–62. doi:10.1097/SLA.0b013e3181896278. PMID:18948815.
   PubMed Web of Science ®Google Scholar
• Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530–4. doi:10.1038/17401. PMID:10028970.
   PubMed Web of Science ®Google Scholar
• Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128–35. doi:10.1038/nm0202-128. PMID:11821896.
   PubMed Web of Science ®Google Scholar
• Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31(5):335–40. doi:10.1016/S0009-9120(98)00045-9. PMID:9721431.
   PubMed Web of Science ®Google Scholar
• Ghidini M, Petrelli F, Ghidini A, Tomasello G, Hahne JC, Passalacqua R, et al. Clinical development of mTor inhibitors for renal cancer. Expert Opin Invest Drugs. 2017;26(11):1229–37. doi:10.1080/13543784.2017.1384813.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Yamashita T, Okada H, Oishi N, Sunagozaka H, Nio K, et al. A novel mTOR inhibitor; Anthracimycin for the treatment of human hepatocellular carcinoma. Anticancer Res. 2017;37(7):3397–403. PMID:28668827.
   PubMed Web of Science ®Google Scholar
• Jain A, Reyes J, Kashyap R, Rohal S, Abu-Elmagd K, Starzl T, et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg. 1999;230(3):441–8; discussion 8–9. doi:10.1097/00000658-199909000-00016. PMID:10493490.
   PubMed Web of Science ®Google Scholar
• Schumacher G, Oidtmann M, Rueggeberg A, Jacob D, Jonas S, Langrehr JM, et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol. 2005;11(10):1420–5. doi:10.3748/wjg.v11.i10.1420. PMID:15770715.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan Criteria. Transplantation Proc. 2008;40(10):3548–53. doi:10.1016/j.transproceed.2008.03.165.
   PubMed Web of Science ®Google Scholar
• Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transplantation. 2008;14(5):633–8. doi:10.1002/lt.21420. PMID:18324656.
   PubMed Web of Science ®Google Scholar
• Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E, et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transplantation. 2009;15(12):1834–42. doi:10.1002/lt.21953. PMID:19938137.
   PubMed Web of Science ®Google Scholar
• Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatol (Baltimore, Md). 2010;51(4):1237–43. doi:10.1002/hep.23437.
   PubMed Web of Science ®Google Scholar
• Vivarelli M, Dazzi A, Zanello M, Cucchetti A, Cescon M, Ravaioli M, et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation. 2010;89(2):227–31. doi:10.1097/TP.0b013e3181c3c540. PMID:20098287.
   PubMed Web of Science ®Google Scholar
• Liang W, Wang D, Ling X, Kao AA, Kong Y, Shang Y, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl. 2012;18(1):62–9. doi:10.1002/lt.22441. PMID:21964956.
   PubMed Web of Science ®Google Scholar
• Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Alimentary Pharmacol Therapeutics. 2013;37(4):411–9. doi:10.1111/apt.12185.
   PubMed Web of Science ®Google Scholar
• Geissler EK, Schnitzbauer AA, Zölke C, Lamby PE, Proneth A, Duvoux C, et al. Sirolimus use in liver transplant recipients with Hepatocellular carcinoma: A randomized, Multicenter, open-label phase 3 Trial. Transplantation. 2016;100(1):116–25. doi:10.1097/TP.0000000000000965. PMID:26555945.
   PubMed Web of Science ®Google Scholar
• Xu SL, Zhang YC, Wang GY, Yang Q, Liu B, Zhang J, et al. Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2016;40(6):674–81. doi:10.1016/j.clinre.2016.03.006. PMID:27825633.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. doi:10.1007/s10654-010-9491-z. PMID:20652370.
   PubMed Web of Science ®Google Scholar
• Dayan N, Filion KB, Okano M, Kilmartin C, Reinblatt S, Landry T, et al. Cardiovascular risk following fertility therapy: Systematic review and meta-analysis. J Am College Cardiol. 2017;70(10):1203–13. doi:10.1016/j.jacc.2017.07.753.
   PubMed Web of Science ®Google Scholar
• Feng L, Ni Z, Song S, Lin F, Fu H, Wang Z, et al. Effect of conversion to sirolimus-based immunosuppression on tumor recurrence after liver transplantation for hepatocellular carcinoma beyond the Standard Milan Criteria. Acad J Second Military Medical University. 2012;33(6):642–5.
   Google Scholar
• Zhao X, Wang M, Wu J, Lin D, Guo Q, Lai W, et al. [A retrospective cohort study regarding the effect of sirolimus-based immunosuppression protocol on the long-term survival of hepatocellular carcinoma patients after liver transplantation]. Zhonghua Wai Ke Za Zhi [Chinese J Surg]. 2014;52(4):245–8.
   PubMedGoogle Scholar
• Shen C, Peng C, Shen B, Zhu Z, Xu N, Li T, et al. Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation. Oncotarget. 2016;7(38):62647–56. doi:10.18632/oncotarget.11591. PMID:27577068.
   PubMedGoogle Scholar
• Yanik EL, Chinnakotla S, Gustafson SK, Snyder JJ, Israni AK, Segev DL, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma. Liver Transplantation. 2016;22(5):627–34. doi:10.1002/lt.24395. PMID:26784951.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9. doi:10.1056/NEJM199603143341104. PMID:8594428.
   PubMed Web of Science ®Google Scholar
• Vibert E, Duclos-Vallee JC, Ghigna MR, Hoti E, Salloum C, Guettier C, et al. Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection. Hepatology (Baltimore, Md). 2011;53(2):475–82. doi:10.1002/hep.24062. PMID:21274869.
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Mamou C, Rodriguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transplant Int. 2014;27(10):1039–49. doi:10.1111/tri.12372.
   PubMed Web of Science ®Google Scholar
• Decaens T, Luciani A, Itti E, Hulin A, Roudot-Thoraval F, Laurent A, et al. Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma. Dig Liver Dis. 2012;44(7):610–6. doi:10.1016/j.dld.2012.02.005. PMID:22459565.
   PubMedGoogle Scholar
• Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–66. doi:10.1111/liv.12818. PMID:25752327.
   PubMed Web of Science ®Google Scholar
• Alamo JM, Barrera L, Casado MD, Bernal C, Marin LM, Suarez G, et al. Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation. Transplantation Proc. 2009;41(6):2181–3. doi:10.1016/j.transproceed.2009.06.083.
   PubMed Web of Science ®Google Scholar
• Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol (Northwood, London, England). 2010;27(2):255–61. doi:10.1007/s12032-009-9201-4.
   PubMed Web of Science ®Google Scholar
• Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Cur Opin Pharmacol. 2008;8(4):393–412. doi:10.1016/j.coph.2008.08.004.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–93.. doi:10.1016/j.cell.2012.03.017. PMID:22500797.
   PubMed Web of Science ®Google Scholar
• Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, et al. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer. 2012;11:85. doi:10.1186/1476-4598-11-85. PMID:23167739.
   PubMed Web of Science ®Google Scholar
• Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003;17(15):1829–34. doi:10.1101/gad.1110003. PMID:12869586.
   PubMed Web of Science ®Google Scholar
• Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A. 2002;99(21):13571–6. doi:10.1073/pnas.202476899. PMID:12271141.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Licinio R, Carr BI, Di Leo A, Barone M. MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma. Exp Rev Gastroenterol Hepatol. 2015;9(7):993–1003. doi:10.1586/17474124.2015.1040763.
   PubMed Web of Science ®Google Scholar